Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA
Current and future immunotherapy targets in autoimmune neurology.
Regenerative cellular therapies for neurologic diseases.
A Unified Frequency Domain Model to Study the Effect of Demyelination on Axonal Conduction.
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Myelin Gordon Research Conference
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Multiple sclerosis: A lifestyle disease?
Pathogenic implications of iron accumulation in multiple sclerosis.
Product Portfolio, Meda
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
Episode 3 with Drs. Daren Austin and Susan Van Meter on the MIRROR trial of ofatumumab
Erratum to: Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination.
Mitoxantrone: benefits and risks in multiple sclerosis patients.
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Masitinib in Patients with Progressive or Relapse-Free Secondary Multiple Sclerosis
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Multiple sclerosis in 2014: Progress in MS-classification, mechanisms and treatment.

Pages